EXEL(Exelixis, Inc.) 的财务报表:医疗保健,生物技术。数据来自 SEC 公开申报与市场行情,不构成投资建议。
| 科目 | FY 截至 2021-12-31 | FY 截至 2022-12-30 | FY 截至 2023-12-29 | FY 截至 2025-01-03 | FY 截至 2026-01-02 |
|---|---|---|---|---|---|
| 营业收入 | $1.43B | $1.61B | $1.83B | $2.17B | $2.32B |
| 毛利润 | $1.38B | $1.55B | $1.76B | $2.09B | $2.24B |
| 营业利润 | $286.67M | $201.48M | $170.88M | $604.62M | $872.19M |
| 净利润 | $231.06M | $182.28M | $207.76M | $521.27M | $782.57M |
| 经营现金流 | $400.80M | $362.61M | $333.32M | $699.97M | $884.27M |
| 自由现金流 | $346.58M | $334.91M | $292.86M | $671.54M | $875.84M |
| 摊薄每股收益 | $0.72 | $0.56 | $0.65 | $1.76 | $2.78 |